0001209191-23-048489.txt : 20230906
0001209191-23-048489.hdr.sgml : 20230906
20230906175058
ACCESSION NUMBER: 0001209191-23-048489
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230901
FILED AS OF DATE: 20230906
DATE AS OF CHANGE: 20230906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Huizenga Theodore Alan
CENTRAL INDEX KEY: 0001603347
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36276
FILM NUMBER: 231240377
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc.
CENTRAL INDEX KEY: 0001515673
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 272546083
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 415-483-8800
MAIL ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-01
0
0001515673
Ultragenyx Pharmaceutical Inc.
RARE
0001603347
Huizenga Theodore Alan
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO
CA
94949
0
1
0
0
SVP, Chief Accounting Officer
0
Common Stock
2023-09-01
4
S
0
883
37.04
D
23864
D
Common Stock
2023-09-01
4
S
0
87
38.23
D
23777
D
The sale reported on this row of the Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
The total amount of securities beneficially owned by the Reporting Person reflected in Table 1, Column 5 of this Form 4 reflects the correction of a typographical error in a previously filed Form 4 filed on April 18, 2023 ("April 2023 Form 4"). The corrected total amount of securities beneficially owned by the Reporting Person in Table 1, Column 5 of the April 2023 Form 4 is 21,520. The corrected total amount of securities beneficially owned by the Reported Person in Table 1, Column 5 of the Form 4 filed on behalf of the Reporting Person on May 10, 2023 is 24,747.
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
/s/ Karah Parschauer, attorney-in-fact
2023-09-06